Na+/K+-ATPase α1 subunit, a novel therapeutic target for hepatocellular carcinoma-Reference-Cited by-同舟云学术

Na+/K+-ATPase α1 subunit, a novel therapeutic target for hepatocellular carcinoma

Published:2015-08-18 Issue:29 Volume:6 Page:28183-28193
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Zhuang Liping¹,Xu Litao¹,Wang Peng¹,Jiang Yan²,Yong Pan²,Zhang Chenyue¹,Zhang Haibin³,Meng Zhiqiang¹,Yang Peiying²

Affiliation:

1. Department of Integrative Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Collaborative Innovation Center for Cancer Medcine, Shanghai, China

2. Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3. Eastern Hepatobilliary Surgery Hospital, Second Military Medical University, Shanghai, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Occupational second-hand smoke exposure: A comparative shotgun proteomics study on nasal epithelia from healthy restaurant workers;Environmental Toxicology and Pharmacology;2024-06

2. Hypomethylation of ATP1A1 Is Associated with Poor Prognosis and Cancer Progression in Triple-Negative Breast Cancer;Cancers;2024-04-25

3. ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy;Cancer Cell International;2024-01-04

4. Potassium channels as novel molecular targets in hepatocellular carcinoma (Review);Oncology Reports;2023-08-24

5. ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy;2023-08-07